1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,080 | 1,254 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | NFL Biosciences SA: NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation | 216 | Business Wire | In-depth understanding of the mechanism of action of its drug candidates based on new data Enhanced clinical development strategy based on these advances, targeting clinical efficiencies... ► Artikel lesen | |
| 08.12.25 | NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application | 244 | Business Wire | These results represent the first scientific milestone expected by regulatory agencies and potential pharmaceutical partners New patent application currently in preparation Results... ► Artikel lesen | |
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | NFL Biosciences SA: NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners | 333 | Business Wire | Regulatory News:
NFL Biosciences SA (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today presents... ► Artikel lesen | |
| 20.10.25 | NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA | 404 | Business Wire | Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO... ► Artikel lesen | |
| 16.10.25 | NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development | 405 | Business Wire | Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions... ► Artikel lesen | |
| 01.09.25 | NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT) | 735 | Business Wire | The SRNT, the world's leading scientific society dedicated to nicotine and tobacco research, publishes the results of the CESTO II study in its reference journal, thereby ensuring their optimal... ► Artikel lesen | |
| 28.07.25 | NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101 | 364 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces... ► Artikel lesen | |
| 22.07.25 | NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction | 370 | Business Wire | A €600,000 "Innovation Advance" repayable advance granted by Bpifrance
€600,000 in bank loans granted by Société Générale and Banque Populaire, the company's long-standing banking partners... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,360 | +1,40 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen NFL BIOSCIENCES SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,150 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.